JP2021503457A5 - - Google Patents

Download PDF

Info

Publication number
JP2021503457A5
JP2021503457A5 JP2020526610A JP2020526610A JP2021503457A5 JP 2021503457 A5 JP2021503457 A5 JP 2021503457A5 JP 2020526610 A JP2020526610 A JP 2020526610A JP 2020526610 A JP2020526610 A JP 2020526610A JP 2021503457 A5 JP2021503457 A5 JP 2021503457A5
Authority
JP
Japan
Prior art keywords
cancer
kinase
inhibitor
agent
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020526610A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021503457A (ja
JP7349155B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/061579 external-priority patent/WO2019099873A1/en
Publication of JP2021503457A publication Critical patent/JP2021503457A/ja
Publication of JP2021503457A5 publication Critical patent/JP2021503457A5/ja
Application granted granted Critical
Publication of JP7349155B2 publication Critical patent/JP7349155B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020526610A 2017-11-17 2018-11-16 二元的なmekシグナル伝達の低減によるがん治療 Active JP7349155B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587707P 2017-11-17 2017-11-17
US62/587,707 2017-11-17
PCT/US2018/061579 WO2019099873A1 (en) 2017-11-17 2018-11-16 Cancer therapy by degrading dual mek signaling

Publications (3)

Publication Number Publication Date
JP2021503457A JP2021503457A (ja) 2021-02-12
JP2021503457A5 true JP2021503457A5 (cg-RX-API-DMAC10.html) 2021-12-02
JP7349155B2 JP7349155B2 (ja) 2023-09-22

Family

ID=66538820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526610A Active JP7349155B2 (ja) 2017-11-17 2018-11-16 二元的なmekシグナル伝達の低減によるがん治療

Country Status (11)

Country Link
US (2) US11510919B2 (cg-RX-API-DMAC10.html)
EP (1) EP3710433A4 (cg-RX-API-DMAC10.html)
JP (1) JP7349155B2 (cg-RX-API-DMAC10.html)
KR (1) KR20200090771A (cg-RX-API-DMAC10.html)
CN (1) CN111491927A (cg-RX-API-DMAC10.html)
AU (1) AU2018368453B2 (cg-RX-API-DMAC10.html)
CA (1) CA3082575A1 (cg-RX-API-DMAC10.html)
IL (1) IL274663B2 (cg-RX-API-DMAC10.html)
MX (1) MX2020004991A (cg-RX-API-DMAC10.html)
SG (1) SG11202004384YA (cg-RX-API-DMAC10.html)
WO (1) WO2019099873A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3082575A1 (en) * 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling
CA3114385A1 (en) * 2018-10-05 2020-04-09 The Board Of Trustees Of The University Of Illinois Combination therapy for the treatment of uveal melanoma
CA3142157A1 (en) * 2019-05-30 2020-12-03 The Board Of Trustees Of The University Of Illinois Procaspase-3 activation and immunotherapy for treatment of cancer
CN115677772B (zh) * 2021-07-30 2023-08-18 浙江大学智能创新药物研究院 一种用于egfr激酶抑制剂的化合物、组合物及其应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5723459A (en) 1991-05-09 1998-03-03 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5844001A (en) 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
FR2757866B1 (fr) 1996-12-30 2004-12-17 Catalyse Polymeres comportant des groupes ammoniums quaternaires, leur utilisation pour la fabrication d'un materiau a propretes antibacteriennes et leurs procedes de preparation
US6403765B1 (en) 1998-06-16 2002-06-11 Thomas Jefferson University Truncated Apaf-1 and methods of use thereof
US6303329B1 (en) 1998-07-27 2001-10-16 Pharmacia & Upjohn Company Method for autoactivation of procaspase 8
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
AU2002211602A1 (en) 2000-10-11 2002-04-22 Johns Hopkins University Polymer controlled delivery of a therapeutic agent
WO2002048329A2 (en) 2000-11-20 2002-06-20 Idun Pharmaceuticals, Inc. Membrane derived caspase-3, compositions comprising the same and methods of use therefor
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
WO2004066958A2 (en) 2003-01-30 2004-08-12 The Trustees Of Princeton University Caspase-9:bir3 domain of xiap complexes and methods of use
US7632972B2 (en) 2003-10-30 2009-12-15 The Board Of Trustees Of The University Of Illionis Compounds and methods for treatment of cancer and modulation of programmed cell death for melanoma and other cancer cells
BRPI0417498A (pt) 2003-12-09 2007-05-29 Us Gov Health & Human Serv método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
WO2008134474A2 (en) 2007-04-27 2008-11-06 The Board Of Trustees Of The University Of Illinois Compositions and methods including cell death inducers and procaspase activation
US20070049602A1 (en) 2005-05-26 2007-03-01 The Board Of Trustees Of The University Of Illinois Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3
CN101184491A (zh) 2005-05-26 2008-05-21 伊利诺伊大学评议会 包括活化半胱天冬酶-3酶原的癌细胞内选择性细胞凋亡诱导
RU2408584C2 (ru) 2005-06-23 2011-01-10 Мерк Шарп Энд Домэ Корп. Ингибиторы тирозинкиназы
ES2580108T3 (es) 2005-07-11 2016-08-19 Aerie Pharmaceuticals, Inc Compuestos de isoquinolina
TWI373473B (en) 2005-09-02 2012-10-01 Otsuka Pharma Co Ltd Anticancer agent
WO2007033374A2 (en) 2005-09-16 2007-03-22 Schering Corporation Pharmaceutical compositions and methods using temozolomide and a protein kinase inhibitor
US20070111936A1 (en) 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
CA2651395A1 (en) 2006-05-19 2007-11-29 Board Of Trustees Of The University Of Illinois Phosphorous containing compounds including triphenylmethylphosphonate esters for the treatment of melanoma and other cancers
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明(cyclopamine)類似物類
EA018503B1 (ru) 2007-07-20 2013-08-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Замещенные производные индазола, активные как ингибиторы киназы
RU2360692C1 (ru) 2007-12-21 2009-07-10 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, стимулирующее апоптоз клеток лейкемии человека
BRPI0907162A2 (pt) 2008-01-11 2015-07-07 Univ California Composto, composição farmacêutica e métodos para ativar procaspase executora 3, 6 e/ou 7 e para tratar um estado de doença em um mamífero
US20100291214A1 (en) 2008-12-23 2010-11-18 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
US8574289B2 (en) 2009-02-09 2013-11-05 St. Jude Medical, Cardiology Division, Inc. Inflatable minimally invasive system for delivering and securing an annular implant
CN106946812B (zh) 2009-02-09 2020-10-09 伊利诺伊大学评议会 作为个性化抗癌药的胱天蛋白酶原活化化合物的设计、合成和评价
CN102481269B (zh) 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
AU2009347159B2 (en) 2009-05-27 2015-09-03 Cephalon, Inc. Combination therapy for the treatment of multiple myeloma
WO2010151746A2 (en) 2009-06-26 2010-12-29 Armark Authentication Technologies, Llc Three-dimensional microfiber extrudate structure and process for forming three-dimensional microfiber extrudate structure
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
WO2012118978A1 (en) 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers
US20140348819A1 (en) 2011-06-24 2014-11-27 Dana-Farber Cancer Institute, Inc. Methods of Treating Cancer
DK3686193T3 (da) * 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
US8916705B2 (en) 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
EP2819661B1 (en) 2012-03-02 2016-11-09 The Board of Trustees of the University of Illionis Potent anticancer activity via dual compound activation
US9399035B2 (en) 2012-03-06 2016-07-26 The Board Of Trustees Of The University Of Illinois Procaspase 3 activation by combination therapy
DK3290035T3 (da) 2012-03-06 2019-08-05 Univ Illinois Procaspase-kombinationsterapi til behandling af cancer
CA2879798C (en) 2012-08-03 2022-05-31 The Board Of Trustees Of The University Of Illinois Procaspase enzyme-activating substituted 2-(4-benzylpiperazin-1-yl)-n'-(2-hydroxybenzylidene)acetohydrazide derivatives and compostions thereof
US10201556B2 (en) 2012-11-06 2019-02-12 Interna Technologies B.V. Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway
CN105163584B (zh) 2013-03-05 2019-06-04 田纳西大学研究基金会 用于治疗癌症的化合物
WO2014193898A1 (en) 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
TWI839690B (zh) 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
GB201320302D0 (en) * 2013-11-18 2014-01-01 Element Six Ltd Diamond components for quantum imaging sensing and information processing devices
JP7033451B2 (ja) * 2015-06-05 2022-03-10 ザ ボード オブ トラスティーズ オブ ザ ユニバーシテイ オブ イリノイ Pac-1併用療法
BR112018012255A2 (pt) 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CA3082575A1 (en) * 2017-11-17 2019-05-23 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual mek signaling

Similar Documents

Publication Publication Date Title
CN105338977B (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
RU2018120330A (ru) Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
US12295955B2 (en) TTP phosphorylation for the identification of personalized medicines
CN112867512A (zh) 联合疗法
JP2018535923A (ja) 胆道癌の治療
JP2018504416A5 (cg-RX-API-DMAC10.html)
FI4013412T3 (fi) Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
US20190209576A1 (en) Apilimod for use in the treatment of colorectal cancer
CN118201615A (zh) 喹唑啉酮化合物用于治疗癌症的新用途
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
IL274663B2 (en) Cancer therapy by degrading dual mek signaling
KR20130073948A (ko) 암 치료를 위한 새로운 병용 요법
JP2019519543A (ja) Pde−4阻害剤の局所処方物およびそれらの使用方法
KR20210010524A (ko) 샘낭암종을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물
CA2985379C (en) Micronized pharmaceutical compositions for treatment of angiogenisis conditions
US11672812B2 (en) Methods and compositions comprising tyrosine kinase inhibitor and triptolide for the treatment of cancer
Moehler et al. New chemotherapeutic strategies in colorectal cancer
JP5945863B2 (ja) 腎細胞がん治療剤
Chow et al. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer
AU2019384802A1 (en) Pharmaceutical methods
TW201932120A (zh) 用於具有異檸檬酸脫氫酶突變的腫瘤的藥物組成物與抗腫瘤劑及其應用
US11179395B2 (en) Treating melanoma with mebendazole and a mitogen-activated kinase inhibitor
JP7227968B2 (ja) 抗腫瘍剤及び腫瘍治療方法
WO2025127108A1 (ja) N-(4-(4-アミノ-6-エチニル-5-(キノリン-3-イル)-7H-ピロロ[2,3-d]ピリミジン-7-イル)ビシクロ[2.2.1]ヘプタン-1-イル)-5-メチルピラジン-2-カルボキサミド又はその塩を有効成分とする脳移行性腫瘍治療剤
RU2774612C2 (ru) Терапевтические комбинации, содержащие ингибитор raf и ингибитор erk